VYNE Therapeutics
VYNE
93 hedge funds and large institutions have $92.7M invested in VYNE Therapeutics in 2020 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 29 increasing their positions, 10 reducing their positions, and 9 closing their positions.
444% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 9
190% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 10
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
72% more funds holding
Funds holding: 54 → 93 (+39)
44% more capital invested
Capital invested by funds: $64.3M → $92.7M (+$28.4M)
0.01% less ownership
Funds ownership: 0.8% → 0.79% (-0.01%)
40% less call options, than puts
Call options by funds: $167K | Put options by funds: $277K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$28.9M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$16.7M |
| 3 |
DA
DSC Advisors
Chicago,
Illinois
|
+$9.04M |
| 4 |
BlackRock
New York
|
+$8.75M |
| 5 |
6CM
683 Capital Management
New York
|
+$8.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$10.1M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$5.94M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$3.7M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$3.24M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.4M |
VYNE Hedge Fund Activity: Q1 2020 in Review
93 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2020, worth a combined $92.7M — up 44% from $64.3M a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new VYNE positions and 9 closed out — a net gain of 40 holders — while 29 added to existing stakes and 10 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $28.9M. The largest seller was First Manhattan, exiting entirely with an estimated $10.1M sold.
- 93 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2020, up from 54 in Q4 2019.
- Funds reported $92.7M of VYNE Therapeutics stock for Q1 2020, up 44% quarter-over-quarter.
- 49 funds opened new VYNE Therapeutics positions in Q1 2020 and 9 closed out, a net change of +40 holders.
- The largest VYNE Therapeutics buyer in Q1 2020 was Perceptive Advisors, an estimated $28.9M added.
- The largest VYNE Therapeutics seller in Q1 2020 was First Manhattan, an estimated $10.1M sold.
Based on aggregated 13F filings for Q1 2020.